Dupixent ist ein Biologikum (Biological) mit Zulassung bei schwerer Neurodermitis. Eine schwere Infektion mit Coccidioidomycosis wurde erfolgreich mit Interferon-γ und Dupilumab (im New England Journal of Medicine publiziert) behandelt:
«Risk factors for disseminated coccidioidomycosis include pregnancy, immunosuppression, HIV and acquired immunodeficiency syndrome, and monogenic defects of the interleukin-12–interferon-γ axis2— all states in which type 2 immunity dominates over type 1 immunity. In this report, we showed that treatment with interferon-γ (augmenting type 1 immunity) in combination with dupilumab (suppressing type 2 immunity) resulted in complete resolution of disease in a patient with life-threatening disseminated coccidioidomycosis who had no known monogenic immunodeficiency. These observations imply that a relative insufficiency of type 1 immunity combined with strong type 2 responses confers susceptibility to disseminated coccidioidomycosis. We propose that restoring the balance between type 1 and type 2 immunity enables clinical improvement and that the relative differentiation state of helper T cells may serve as a useful biomarker in this disease.»